Esther Rajavelu Sells 87,917 Shares of Spero Therapeutics (NASDAQ:SPRO) Stock

Spero Therapeutics, Inc. (NASDAQ:SPRO) insider Esther Rajavelu sold 87,917 shares of the business’s stock in a transaction on Friday, February 6th. The shares were sold at an average price of $2.36, for a total transaction of $207,484.12. Following the transaction, the insider owned 1,012,091 shares in the company, valued at $2,388,534.76. This trade represents a 7.99% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink.

Esther Rajavelu also recently made the following trade(s):

• On Monday, February 2nd, Esther Rajavelu sold 18,442 shares of Spero Therapeutics stock. The stock was sold at an average price of $2.20, for a total transaction of $40,572.40.

Spero Therapeutics Trading Down 2.5%

Shares of SPRO stock traded down $0.06 during trading hours on Monday, reaching $2.36. 349,025 shares of the stock were exchanged, compared to its average volume of 328,467. The firm has a market capitalization of $132.96 million, a price-to-earnings ratio of -2.99 and a beta of 1.45. Spero Therapeutics, Inc. has a 12-month low of $0.51 and a 12-month high of $3.22. The company’s 50-day moving average price is $2.35 and its 200-day moving average price is $2.24.

Spero Therapeutics (NASDAQ:SPRO) last posted its quarterly earnings data on Thursday, November 13th. The company reported ($0.13) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.25) by $0.12. Spero Therapeutics had a negative net margin of 108.11% and a negative return on equity of 125.91%. The company had revenue of $5.44 million for the quarter, compared to analyst estimates of $12.00 million. On average, sell-side analysts expect that Spero Therapeutics, Inc. will post -1.2 EPS for the current year.

Analysts Set New Price Targets

Several equities analysts have commented on the company. Zacks Research downgraded Spero Therapeutics from a “strong-buy” rating to a “hold” rating in a research report on Monday, October 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Spero Therapeutics in a report on Thursday, January 22nd. Finally, Wall Street Zen upgraded shares of Spero Therapeutics from a “hold” rating to a “buy” rating in a report on Sunday, January 11th. One investment analyst has rated the stock with a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, the company has an average rating of “Reduce”.

Hedge Funds Weigh In On Spero Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Invesco Ltd. purchased a new position in shares of Spero Therapeutics in the 2nd quarter valued at $43,000. Dimensional Fund Advisors LP bought a new stake in Spero Therapeutics during the third quarter valued at about $55,000. Quadrature Capital Ltd purchased a new position in Spero Therapeutics in the second quarter valued at about $90,000. Axxcess Wealth Management LLC bought a new position in Spero Therapeutics in the second quarter worth about $94,000. Finally, XTX Topco Ltd bought a new position in Spero Therapeutics in the second quarter worth about $100,000. Institutional investors own 25.60% of the company’s stock.

About Spero Therapeutics

Spero Therapeutics is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapies to address multidrug‐resistant bacterial infections. Headquartered in Boston, Massachusetts, the company aims to advance a pipeline of oral and intravenous antibiotic candidates designed to treat serious infectious diseases that pose significant public health challenges.

The company’s lead candidate, tebipenem HBr, is an oral carbapenem antibiotic being developed for the treatment of complicated urinary tract infections caused by resistant Gram‐negative pathogens.